Your browser doesn't support javascript.
loading
Structure-based discovery of conformationally selective inhibitors of the serotonin transporter.
Singh, Isha; Seth, Anubha; Billesbølle, Christian B; Braz, Joao; Rodriguiz, Ramona M; Roy, Kasturi; Bekele, Bethlehem; Craik, Veronica; Huang, Xi-Ping; Boytsov, Danila; Pogorelov, Vladimir M; Lak, Parnian; O'Donnell, Henry; Sandtner, Walter; Irwin, John J; Roth, Bryan L; Basbaum, Allan I; Wetsel, William C; Manglik, Aashish; Shoichet, Brian K; Rudnick, Gary.
Afiliação
  • Singh I; Department of Pharmaceutical Chemistry, University of California, San Francisco, 1700 4th St., Byers Hall Suite 508D, San Francisco, CA 94143, USA.
  • Seth A; Department of Pharmacology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520-8066, USA.
  • Billesbølle CB; Department of Pharmaceutical Chemistry, University of California, San Francisco, 1700 4th St., Byers Hall Suite 508D, San Francisco, CA 94143, USA.
  • Braz J; Department of Anatomy, University of California, San Francisco, San Francisco, CA 94143, USA.
  • Rodriguiz RM; Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA; Mouse Behavioral and Neuroendocrine Analysis Core Facility, Duke University Medical Center, Durham, NC 27710, USA.
  • Roy K; Department of Pharmacology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520-8066, USA.
  • Bekele B; Department of Pharmacology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520-8066, USA.
  • Craik V; Department of Anatomy, University of California, San Francisco, San Francisco, CA 94143, USA.
  • Huang XP; Department of Pharmacology, NIMH Psychoactive Drug Screening Program, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Boytsov D; Institute of Pharmacology, Center for Physiology and Pharmacology, Medical University of Vienna, 1090 Vienna, Austria.
  • Pogorelov VM; Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA.
  • Lak P; Department of Pharmaceutical Chemistry, University of California, San Francisco, 1700 4th St., Byers Hall Suite 508D, San Francisco, CA 94143, USA.
  • O'Donnell H; Department of Pharmaceutical Chemistry, University of California, San Francisco, 1700 4th St., Byers Hall Suite 508D, San Francisco, CA 94143, USA.
  • Sandtner W; Institute of Pharmacology, Center for Physiology and Pharmacology, Medical University of Vienna, 1090 Vienna, Austria.
  • Irwin JJ; Department of Pharmaceutical Chemistry, University of California, San Francisco, 1700 4th St., Byers Hall Suite 508D, San Francisco, CA 94143, USA.
  • Roth BL; Department of Pharmacology, NIMH Psychoactive Drug Screening Program, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hi
  • Basbaum AI; Department of Anatomy, University of California, San Francisco, San Francisco, CA 94143, USA. Electronic address: allan.basbaum@ucsf.edu.
  • Wetsel WC; Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA; Mouse Behavioral and Neuroendocrine Analysis Core Facility, Duke University Medical Center, Durham, NC 27710, USA; Departments of Cell Biology and Neurobiology, Duke University Medical Center, Du
  • Manglik A; Department of Pharmaceutical Chemistry, University of California, San Francisco, 1700 4th St., Byers Hall Suite 508D, San Francisco, CA 94143, USA; Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, CA 94115, USA. Electronic address: aashish.mang
  • Shoichet BK; Department of Pharmaceutical Chemistry, University of California, San Francisco, 1700 4th St., Byers Hall Suite 508D, San Francisco, CA 94143, USA. Electronic address: bshoichet@gmail.com.
  • Rudnick G; Department of Pharmacology, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520-8066, USA. Electronic address: gary.rudnick@yale.edu.
Cell ; 186(10): 2160-2175.e17, 2023 05 11.
Article em En | MEDLINE | ID: mdl-37137306
The serotonin transporter (SERT) removes synaptic serotonin and is the target of anti-depressant drugs. SERT adopts three conformations: outward-open, occluded, and inward-open. All known inhibitors target the outward-open state except ibogaine, which has unusual anti-depressant and substance-withdrawal effects, and stabilizes the inward-open conformation. Unfortunately, ibogaine's promiscuity and cardiotoxicity limit the understanding of inward-open state ligands. We docked over 200 million small molecules against the inward-open state of the SERT. Thirty-six top-ranking compounds were synthesized, and thirteen inhibited; further structure-based optimization led to the selection of two potent (low nanomolar) inhibitors. These stabilized an outward-closed state of the SERT with little activity against common off-targets. A cryo-EM structure of one of these bound to the SERT confirmed the predicted geometry. In mouse behavioral assays, both compounds had anxiolytic- and anti-depressant-like activity, with potencies up to 200-fold better than fluoxetine (Prozac), and one substantially reversed morphine withdrawal effects.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores Seletivos de Recaptação de Serotonina / Proteínas da Membrana Plasmática de Transporte de Serotonina / Bibliotecas de Moléculas Pequenas / Ibogaína Limite: Animals Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Inibidores Seletivos de Recaptação de Serotonina / Proteínas da Membrana Plasmática de Transporte de Serotonina / Bibliotecas de Moléculas Pequenas / Ibogaína Limite: Animals Idioma: En Ano de publicação: 2023 Tipo de documento: Article